Author + information
- Greg Lip,
- Menno Huisman,
- Hans-Christoph Diener,
- Sergio Dubner,
- Changsheng Ma,
- Kenneth Rothman,
- Shihai Lu,
- Miney Paquette,
- Lionel Riou França,
- Dorothee B. Bartels,
- Christine Teutsch and
- Jonathan Halperin
Background: The safety and effectiveness of dabigatran etexilate (DE) for stroke prevention in non-valvular AF (NVAF) has been shown in clinical and database studies. Data from clinical practice with >1 year observation are less accessible. GLORIA-AF is a prospective, global registry of patients with newly diagnosed NVAF at risk of stroke. This report describes 2-year clinical outcomes of patients receiving either the standard dose of DE 150 mg BID (DE 150) or the lower dose, DE 110 mg BID (DE 110).
Methods: This report was performed when ∼3000 patients had received DE in Phase II of GLORIA-AF with up to 2 years follow-up. Baseline characteristics and event rates (incidence rates with 95% CI) are described without adjustment for confounding.
Results: Overall, 2937 patients received DE for a mean of 17.6 ± 9.4 months. Most (59.5%) received DE 150, 37.6% DE 110 and 2.5% DE 75 mg BID. Compared with DE 110, patients receiving DE 150 were younger (median 68 vs 76 years), had lower CHA2DS2VASc scores (mean 2.9 vs 3.7) and fewer comorbidities (e.g., myocardial infarction or heart failure). For DE 150 and DE 110 rates of stroke were 0.56 and 0.67 per 100 patient-years, respectively. Major bleeding rates were 1.00 per 100 patient years for DE 150 and 1.16 for DE 110 [see table].
Conclusions: Consistent with observations from other registry and database studies, rates of stroke and major bleeding were low with both DE doses, highlighting their long-term safety and effectiveness in routine clinical practice.
Poster Hall, Hall C
Sunday, March 19, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making
Abstract Category: 8. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias
Presentation Number: 1280-103
- 2017 American College of Cardiology Foundation